Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1500648800HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Even at a discount, Sanofi's pricey cancer drug Zaltrap can't win at NICE

25.03.2014 / Fierce Pharma

The U.K.'s National Institute for Health and Care Excellence has spurned Sanofi's colon cancer treatment Zaltrap once again. And this time, the decision is final. The cost-effectiveness agency dismissed the French company's appeal, despite the offer of a discount.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: